Keros Therapeutics, Inc. Cash and Restricted Cash
Keros Therapeutics, Inc. (KROS) had Cash and Restricted Cash of $259.06 million as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-03
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $259.06M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $282.95M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $288.86M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $694.92M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $259.06M 10-Q · filed 2026-08-03 |
| 2026-03-31 | $282.95M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $288.86M 10-Q · filed 2026-08-03 |
| 2025-09-30 | $694.92M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $691.66M 10-Q · filed 2026-08-03 |
| 2025-03-31 | $721.99M 10-Q · filed 2026-05-14 |
| 2024-12-31 | $561.38M 10-Q · filed 2026-08-03 |
| 2024-09-30 | $532.13M 10-Q · filed 2025-11-05 |
| 2024-06-30 | $407.07M 10-Q · filed 2025-08-06 |
| 2024-03-31 | $443.65M 10-Q · filed 2025-05-06 |
| 2023-12-31 | $332.36M 10-K · filed 2026-03-04 |
| 2023-09-30 | $289.11M 10-Q · filed 2024-11-06 |
| 2023-06-30 | $323.35M 10-Q · filed 2024-08-07 |
| 2023-03-31 | $352.76M 10-Q · filed 2024-05-08 |
| 2022-12-31 | $280.38M 10-K · filed 2025-02-26 |
| 2022-09-30 | $240.75M 10-Q · filed 2023-11-06 |
| 2022-06-30 | $216.95M 10-Q · filed 2023-08-07 |
| 2022-03-31 | $229.91M 10-Q · filed 2023-05-04 |
| 2021-12-31 | $231.37M 10-K · filed 2025-02-26 |
| 2021-09-30 | $222.68M 10-Q · filed 2022-11-03 |
| 2021-06-30 | $237.23M 10-Q · filed 2022-08-04 |
| 2021-03-31 | $255.32M 10-Q · filed 2022-05-05 |
| 2020-12-31 | $265.99M 10-K · filed 2024-02-28 |
| 2020-09-30 | $133.93M 10-Q · filed 2021-11-04 |
| 2020-06-30 | $144.80M 10-Q · filed 2021-08-05 |
| 2020-03-31 | $54.63M 10-Q · filed 2021-05-06 |
| 2019-12-31 | $7.13M 10-K · filed 2022-03-09 |
| 2019-09-30 | $12.65M 10-Q · filed 2020-11-10 |
| 2019-06-30 | $15.68M 10-Q · filed 2020-08-13 |
| 2019-03-31 | $20.88M 10-Q · filed 2020-05-22 |
| 2018-12-31 | $23.39M 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |